Genomics Inform.
2018 Sep;16(3):71-74. 10.5808/GI.2018.16.3.71.
Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer
- Affiliations
-
- 1Genome Editing Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea. kimsy@kribb.re.kr
- 2Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea.
- 3Department of Urology, Chungbuk National University College of Medicine, Cheongju 28644, Korea.
- 4Department of Urology, Chungbuk National University Hospital, Cheongju 28644, Korea.
- 5Department of Functional Genomics, University of Science and Technology, Daejeon 34113, Korea.
- KMID: 2422815
- DOI: http://doi.org/10.5808/GI.2018.16.3.71
Abstract
- Because castration-resistant prostate cancer (CRPC) does not respond to androgen deprivation therapy and has a very poor prognosis, it is critical to identify a prognostic indicator for predicting high-risk patients who will develop CRPC. Here, we report a dataset of whole genomes from four pairs of primary prostate cancer (PC) and CRPC samples. The analysis of the paired PC and CRPC samples in the whole-genome data showed that the average number of somatic mutations per patients was 7,927 in CRPC tissues compared with primary PC tissues (range, 1,691 to 21,705). Our whole-genome sequencing data of primary PC and CRPC may be useful for understanding the genomic changes and molecular mechanisms that occur during the progression from PC to CRPC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Next-Generation Sequencing in Prostate Cancer
- Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer
- Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer
- Precision Medicine in Castration-Resistant Prostate Cancer
- Role of Androgen Receptor in Prostate Cancer: A Review
